Renal Safety of Intravenous Ibandronic Acid in Breast Cancer Patients with Metastatic Bone Disease

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.23, Iss.11, 2003-01, pp. : 707-716

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety of Intravenous Ibandronic Acid for Up to 4 Years in Metastatic Breast Cancer: An Open-Label Trial

By Pecherstorfer Martin

Clinical Drug Investigation, Vol. 26, Iss. 6, 2006-01 ,pp. : 315-322

Adis International

Access to resources Recommend Favorite

Ibandronic acid beneficial in metastatic bone disease

Inpharma, Vol. 1, Iss. 1437, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Ibandronic Acid: A Review of its Use in the Treatment of Bone Metastases of Breast Cancer

By McCormack Paul L. Plosker Greg L.

Drugs, Vol. 66, Iss. 5, 2006-01 ,pp. : 711-728

Adis International

Access to resources Recommend Favorite

Ibandronic acid gives a bone in cancer metastases

Inpharma, Vol. 1, Iss. 1518, 2005-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Apoptosis-mediated Cytotoxic Effects of Ibandronic Acid on Hormone- and Drug-refractory Prostate Cancer Cells and Human Breast Cancer Cells

By Kucukzeybek Y Gorumlu G Cengiz E Karabulut B Sezgin C Atmaca H Sanli UA Uzunoglu S Uslu R

The Journal of International Medical Research, Vol. 38, Iss. 5, 2010-09 ,pp. : 1663-1672

Field House Publishing

Access to resources Recommend Favorite